David Davis
Family · Lemoore, CANPI 1225484975
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,465 of the $34,231 with a category attached, or 83.2%. 25 manufacturers reported payments, led by Medtronic at 57.8% of the total. Reporting peaked in 2022 at $17,375 and has fallen 99.3% since, to $122 in 2025. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 339 payments — averaging $100.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$20K
- Insulet Corporation$11K
- Amgen$1K
- Novo Nordisk$592
- Lilly USA, LLC$281
- Sanofi-aventis U.S. LLC$250
- plus $2K from 19 others
What the payments were for
- Speaking & faculty fees$28,46583%
- Travel & lodging$3761%
- Food & beverage$5,12615%
- Education$140%
- Gifts$2491%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 17 | $19,788 |
| Insulet Corporation | 77 | $10,554 |
| Amgen(2 entities) | 41 | $1,016 |
| Novo Nordisk | 55 | $592 |
| Lilly USA, LLC | 16 | $281 |
| Sanofi-aventis U.S. LLC | 11 | $250 |
| Esperion Therapeutics, Inc. | 24 | $220 |
| Mannkind Corporation | 10 | $213 |
| Dexcom, Inc. | 24 | $210 |
| Abbott | 17 | $196 |
| AbbVie | 11 | $166 |
| Xeris Pharmaceuticals, Inc. | 7 | $134 |
| Bayer | 6 | $132 |
| Halozyme Inc | 3 | $70 |
| Merck | 3 | $70 |
| Novartis | 3 | $54 |
| Ascendis Pharma Endocrinology Inc | 2 | $50 |
| Nevro Corp. | 2 | $47 |
| Tandem Diabetes Care, Inc. | 2 | $41 |
| AstraZeneca | 2 | $37 |
| Pfizer | 1 | $27 |
| Sumitomo Pharma America, Inc. | 2 | $24 |
| Antares Pharma, Inc. | 1 | $22 |
| Radius Health, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 770G$12,150
- Omnipod$9,450
- Minimed 770G System$3,400
- MINIMED 780G$3,275
- VANTA ADAPTIVESTIM$776
How this compares
$34,231 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 169 | $178,956 |
| FarxigaDapagliflozin Propanediol | 100 | $112,449 |
| RybelsusSemaglutide | 73 | $89,921 |
| JardianceEmpagliflozin | 77 | $82,340 |
| MounjaroTirzepatide | 52 | $52,706 |
| KerendiaFinerenone | 36 | $36,920 |
| TrulicityDulaglutide | 29 | $28,538 |
| TradjentaLinagliptin | 15 | $19,280 |
| EliquisApixaban | 25 | $17,836 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 29 | $14,455 |
| Repatha SureclickEvolocumab | 11 | $13,088 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $8,954 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 11 | $7,390 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $3,049 |
| HumalogInsulin Lispro | 12 | $2,995 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $592 | $268,876242 claims |
| AstraZenecaFarxiga | $37 | $112,449100 claims |
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr | $19 | $109,010103 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $281 | $84,23893 claims |
| BayerKerendia | $132 | $36,92036 claims |
| PfizerEliquis | $27 | $17,83625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Lemoore
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.